Works matching DE "PROGRAMMED death-ligand 1"
Results: 3557
Ubiquitin‐Conjugating Enzyme Ubc13 in Macrophages Suppresses Lung Tumor Progression Through Inhibiting PD‐L1 Expression.
- Published in:
- European Journal of Immunology, 2025, v. 55, n. 2, p. 1, doi. 10.1002/eji.202451118
- By:
- Publication type:
- Article
Correlation between CTNNB1 mutation status and tumour phenotype in hepatitis B virus‐related hepatocellular carcinoma.
- Published in:
- Histopathology, 2025, v. 86, n. 4, p. 547, doi. 10.1111/his.15363
- By:
- Publication type:
- Article
Hypoxia‐inducible factor‐targeting therapy augmented the sensitivity to programmed death ligand‐1 blockade by enhancing interferon‐γ‐induced chemokines in tumor cells.
- Published in:
- International Journal of Cancer, 2025, v. 156, n. 9, p. 1814, doi. 10.1002/ijc.35301
- By:
- Publication type:
- Article
Prognostic impact of PD‐L1 expression in surgically resected EGFR‐mutant lung adenocarcinoma: A real‐world database study in Japan (CReGYT‐01 EGFR study).
- Published in:
- International Journal of Cancer, 2025, v. 156, n. 7, p. 1480, doi. 10.1002/ijc.35270
- By:
- Publication type:
- Article
Exosomal miR‐142‐3p from M1‐polarized macrophages suppresses cell growth and immune escape in glioblastoma through regulating HMGB1‐mediated PD‐1/PD‐L1 checkpoint.
- Published in:
- Journal of Neurochemistry, 2025, v. 169, n. 1, p. 1, doi. 10.1111/jnc.16224
- By:
- Publication type:
- Article
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies.
- Published in:
- British Journal of Clinical Pharmacology, 2025, v. 91, n. 3, p. 748, doi. 10.1111/bcp.16276
- By:
- Publication type:
- Article
An evaluation of durvalumab across the spectrum of urothelial carcinoma.
- Published in:
- Expert Review of Anticancer Therapy, 2024, v. 24, n. 11, p. 1101, doi. 10.1080/14737140.2024.2405104
- By:
- Publication type:
- Article
Comparing PD‐L1 and PD‐1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single‐center, real‐world study.
- Published in:
- International Journal of Cancer, 2025, v. 156, n. 10, p. 1972, doi. 10.1002/ijc.35341
- By:
- Publication type:
- Article
Comparative efficacy and safety of PD‐1 versus PD‐L1 inhibitors in breast cancer treatment: A systematic review and meta analysis.
- Published in:
- International Journal of Cancer, 2025, v. 156, n. 10, p. 1936, doi. 10.1002/ijc.35313
- By:
- Publication type:
- Article
Comparative Effectiveness of First‐Line Pembrolizumab vs. Chemotherapy in aNSCLC: A Norwegian Population‐Based Cohort Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 4, p. 1123, doi. 10.1002/cpt.3591
- By:
- Publication type:
- Article
The Prognostic Significance of PD‐L1 Expression and Associated Tumor‐Infiltrating Lymphocytes in Supraglottic Laryngeal Squamous Cell Carcinoma.
- Published in:
- APMIS, 2025, v. 133, n. 2, p. 1, doi. 10.1111/apm.70005
- By:
- Publication type:
- Article
Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer.
- Published in:
- Journal of Pathology: Clinical Research, 2025, v. 11, n. 1, p. 1, doi. 10.1002/2056-4538.70015
- By:
- Publication type:
- Article
Self‐Assembled Peptide‐Derived Proteolysis‐Targeting Chimera (PROTAC) Nanoparticles for Tumor‐Targeted and Durable PD‐L1 Degradation in Cancer Immunotherapy.
- Published in:
- Angewandte Chemie, 2025, v. 137, n. 5, p. 1, doi. 10.1002/ange.202414146
- By:
- Publication type:
- Article
Treatment with programmed-death-1 inhibitors for non-melanoma skin cancer among immunocompromised patients with subgroup analysis of solid organ transplant patients.
- Published in:
- Oncologist, 2025, v. 30, n. 2, p. 1, doi. 10.1093/oncolo/oyaf022
- By:
- Publication type:
- Article
High serum levels of soluble PD‑1 and PD‑L1 are associated with advanced clinical stages in patients with cervical cancer.
- Published in:
- Biomedical Reports, 2025, v. 22, n. 4, p. N.PAG, doi. 10.3892/br.2025.1948
- By:
- Publication type:
- Article
Peptides-functionalized gold nanostars enhanced degradation of PD-L1 for improved prostate cancer immunotherapy.
- Published in:
- Journal of Biomaterials Applications, 2025, v. 39, n. 10, p. 1188, doi. 10.1177/08853282251319473
- By:
- Publication type:
- Article
Cancer Immunotherapy: An Impossible Dream for the Common Man?
- Published in:
- Indian Journal of Medical & Paediatric Oncology, 2021, v. 42, n. 3, p. 312, doi. 10.4103/ijmpo.ijmpo_199_20
- By:
- Publication type:
- Article
Liquid Biopsy.
- Published in:
- Indian Journal of Medical & Paediatric Oncology, 2021, v. 42, n. 1, p. 77, doi. 10.1055/s-0041-1729434
- By:
- Publication type:
- Article
Current Biomarkers in Non-Small Cell Lung Cancer—The Molecular Pathologist's Perspective.
- Published in:
- Diagnostics (2075-4418), 2025, v. 15, n. 5, p. 631, doi. 10.3390/diagnostics15050631
- By:
- Publication type:
- Article
The role of PD-L1 in EGFR-mutant non-small cell lung cancer.
- Published in:
- Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02089-y
- By:
- Publication type:
- Article
Heterogeneous cellular responses to hyperthermia support combined intraperitoneal hyperthermic immunotherapy for ovarian cancer mouse models.
- Published in:
- Science Translational Medicine, 2025, v. 17, n. 789, p. 1, doi. 10.1126/scitranslmed.adp2124
- By:
- Publication type:
- Article
Efficacy and safety of PD-1/PD-L1 inhibitors alone or in combination in the treatment of metastatic or advanced renal cell carcinoma: a network meta-analysis.
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1524497
- By:
- Publication type:
- Article
Rare Lacrimal Gland Melanoma: A Case Report and Treatment Insights.
- Published in:
- 2025
- By:
- Publication type:
- Case Study
Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis.
- Published in:
- Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02052-x
- By:
- Publication type:
- Article
Link of TMPRSS2 expression with tumor immunogenicity and response to immune checkpoint inhibitors in cancers.
- Published in:
- Journal of Translational Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12967-025-06177-z
- By:
- Publication type:
- Article
Pulmonary Adenocarcinoma with Enteric Differentiation without TTF-1 Expression Is a Very Rare Subtype with Limited Treatment Options and Poor Prognosis.
- Published in:
- Oncology, 2025, v. 103, n. 3, p. 179, doi. 10.1159/000540515
- By:
- Publication type:
- Article
Correlation of HLA-A and HLA-B/C Expression With PD-1 and PD-L1 Expression in Patients With Metastatic Breast Cancer as a Potential Prognosticator of Favorable Survival.
- Published in:
- In Vivo, 2025, v. 39, n. 2, p. 758, doi. 10.21873/invivo.13880
- By:
- Publication type:
- Article
Role of Computed Tomography in Predicting Programmed Death Ligand-1 Positivity in Gastric Adenocarcinoma.
- Published in:
- Journal of Multidisciplinary Healthcare, 2025, v. 18, p. 609, doi. 10.2147/JMDH.S495962
- By:
- Publication type:
- Article
ArfGAP with the SH3 Domain, Ankyrin Repeat and PH Domain 1 Inversely Regulates Programmed Death-Ligand 1 Through Negative Feedback of Phosphorylated Epithelial Growth Factor Receptor and Activation of Nuclear Factor-Kappa B in Non-Small Cell Lung Cancer.
- Published in:
- Cancer Management & Research, 2025, v. 17, p. 91, doi. 10.2147/CMAR.S493368
- By:
- Publication type:
- Article
Phytochemical synergies in BK002: advanced molecular docking insights for targeted prostate cancer therapy.
- Published in:
- Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1504618
- By:
- Publication type:
- Article
Role of PD-L1 in mediating the effect of lipid on ulcerative colitis: a mediation Mendelian randomization study.
- Published in:
- Frontiers in Genetics, 2025, p. 1, doi. 10.3389/fgene.2025.1390605
- By:
- Publication type:
- Article
The interplay between programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) genotypes in cervical carcinomas: findings of a Nigerian Tertiary Hospital.
- Published in:
- Pan African Medical Journal, 2024, v. 48, p. 1, doi. 10.11604/pamj.2024.48.90.42773
- By:
- Publication type:
- Article
Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
Efficacy and safety of PD-1/PD-L1 inhibitors for natural killer/T-cell lymphoma: a single-arm meta-analysis.
- Published in:
- BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-13812-x
- By:
- Publication type:
- Article
Clinical efficacy and safety evaluation of traditional Chinese medicine for nourishing yin and Replenishing qi in combination with PD-1/PD-L1 inhibitors in the treatment of NSCLC patients: a meta-analysis.
- Published in:
- Toxicology Research, 2025, v. 14, n. 1, p. 1, doi. 10.1093/toxres/tfaf013
- By:
- Publication type:
- Article
Efficacy comparison of PD-1/PD-L1 inhibitor monotherapy and combination with PARPis or antiangiogenic agents in advanced or recurrent endometrial cancer: a systematic review and network meta-analysis.
- Published in:
- BMC Women's Health, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12905-025-03612-7
- By:
- Publication type:
- Article
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma.
- Published in:
- JAMA Network Open, 2025, v. 8, n. 2, p. e2461735, doi. 10.1001/jamanetworkopen.2024.61735
- By:
- Publication type:
- Article
Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer.
- Published in:
- 2025
- By:
- Publication type:
- Editorial
Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer.
- Published in:
- 2025
- By:
- Publication type:
- Editorial
Effects of c-Kit Receptor, AKT, and NF-κB Inhibitors on Immune Evasion in Multiple Myeloma Cells.
- Published in:
- Iranian Journal of Allergy, Asthma & Immunology, 2025, v. 24, n. 1, p. 89, doi. 10.18502/ijaai.v24i1.18024
- By:
- Publication type:
- Article
A Critical Role of Intracellular PD-L1 in Promoting Ovarian Cancer Progression.
- Published in:
- Cells (2073-4409), 2025, v. 14, n. 4, p. 314, doi. 10.3390/cells14040314
- By:
- Publication type:
- Article
Lipid-siRNA Conjugates Targeting High PD-L1 Expression as Potential Novel Immune Checkpoint Inhibitors.
- Published in:
- Biomolecules (2218-273X), 2025, v. 15, n. 2, p. 293, doi. 10.3390/biom15020293
- By:
- Publication type:
- Article
Deeper Analysis to Identify the True Benefit of ICIs Immunotherapy in First-Line Treatment for Non-HER2-Positive/HER2-Negative Advanced or Metastatic Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJC).
- Published in:
- Cancers, 2025, v. 17, n. 4, p. 657, doi. 10.3390/cancers17040657
- By:
- Publication type:
- Article
Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer.
- Published in:
- Cancers, 2025, v. 17, n. 4, p. 572, doi. 10.3390/cancers17040572
- By:
- Publication type:
- Article
Treatment Response to Oncolytic Virus in Patient-Derived Breast Cancer and Hypopharyngeal Cancer Organoids: Evaluation via a Microfluidics Organ-on-a-Chip System.
- Published in:
- Bioengineering (Basel), 2025, v. 12, n. 2, p. 146, doi. 10.3390/bioengineering12020146
- By:
- Publication type:
- Article
Evaluating the efficacy and safety of immune checkpoint inhibitors in first and second-line treatments for recurrent and metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis of RCTs with a focus on PD-L1 expression
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1508885
- By:
- Publication type:
- Article
Assessing the Clinical Relevance of Soluble PD-1 and PD-L1: A Multi-Cohort Study Across Diverse Tumor Types and Prognostic Implications.
- Published in:
- Biomedicines, 2025, v. 13, n. 2, p. 500, doi. 10.3390/biomedicines13020500
- By:
- Publication type:
- Article
Therapeutic Applications of Programmed Death Ligand 1 Inhibitors in Small Cell Lung Cancer.
- Published in:
- Biomedicines, 2025, v. 13, n. 2, p. 401, doi. 10.3390/biomedicines13020401
- By:
- Publication type:
- Article
Electroacupuncture Modulates Programmed Cell Death 1 Ligand 1 on Peripheral and Central Nervous Systems in a Mouse Fibromyalgia Pain Model.
- Published in:
- Biomedicines, 2025, v. 13, n. 2, p. 396, doi. 10.3390/biomedicines13020396
- By:
- Publication type:
- Article
Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1200, doi. 10.3390/jcm14041200
- By:
- Publication type:
- Article